Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Post COVID .

ME/CFS
Collaborative Research Center

at the CHU Sainte-Justine/
Université de Montréal

Clinical and scientific studies to understand and discover new treatments for Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS)

Core Aims

What we hope to achieve

Philosophy

Our fundamental philosophy

Science Team

List of scientific collaborators

Research

Current research projects

About the research center

The ME / CFS Collaborative Research Center, established in 2020 at CHU Sainte-Justine /Université de Montréal, increases OMF’s international collaborative efforts through the End ME/CFS Project. Directed by Alain Moreau, PhD, the Quebec, Canada-based laboratory has been researching ME / CFS for several years.

About Alain Moreau, PhD

Alain Moreau, PhD, is a Full Professor in the Department of Stomatology, Faculty of Dentistry and Department of Biochemistry and Molecular Medicine, Faculty of Medicine, at Université de Montréal, Montréal, Québec, Canada. Additionally, Dr. Moreau is the Director of Network for Canadian Oral Health Research. He is the Scientific Director of the Viscogliosi Laboratory in Molecular Genetics of Musculoskeletal Diseases, Sainte-Justine University Research Center, Montréal, Québec.

Dr. Moreau’s chief interests of study are pediatric scoliosis, osteoarthritis, osteoporosis, and Myalgic Encephalomyelitis. Dr. Moreau is a member of the Open Medicine Foundation Scientific Advisory Board and is the Director of the Interdisciplinary Canadian Collaborative Myalgic Encephalomyelitis Research Network, a national research network funded by the Canadian Institute of Health Research.

Core Aims

Fundamental Philosophy

Current Studies

Thrombospondin-1 (TSP-1)

We used a specific stress-test to identify possible biomarkers that could be involved in the onset and/or progression of the symptoms associated with specific vascular instabilities including brain fog, orthostatic intolerance and postural orthostatic tachycardia (POTS) in ME / CFS.

Read More →

Stress-Activated MicroRNAs

Stress-Activated MicroRNAs in ME / CFS Pathogenesis The Problem ME / CFS is a multi-systemic complex chronic disease exhibiting a clinical heterogeneity as main symptoms vary between affected individuals …

Read More →

View our latest news

Scientific Team

To carry out these ambitious collaborations, Dr. Moreau has assembled a team of superb clinicians and scientists with expertise in a wide variety of areas directly relevant to Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) research. 

CHU Sainte-Justine Research Center
Université de Montréal

Alain Moreau

Scientific Director

Anita Franco, MSc

Lab coordinator

Yaned Gaitan MSc 

Research assistant- 
mouse manager

Viorica Lascau MSc 

Research coordinator – certification manager

Sophie Perreault, RN  

Clinical research nurse

Valerie Tremblay, RN

Clinical research nurse

Iurie Caraus, PhD 

Postdoctoral fellow

Wesam Elremaly, PhD

Postdoctoral fellow

Corinne Leveau BSc

PhD student

Evguenia Nepotchatykh BSc

PhD student

Lynda Chalder MSc

PhD student

 

CHU Sainte-Justine Research Center
Université de Montréal

Marie-Yvonne Akoume PhD

Invited professor – ICanCME Research Network investigator

Valérie Marcil PhD

Associate Professor – ICanCME Research Network investigator

University of Vermont

Dawei Li, PhD

Associated Professor – ICanCME Research Network investigator

Jason Kost BSc 

Assistant Professor – ICanCME Research Network investigator

Learn about Our Other OMF Funded Collaborative Research Centers

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

 

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of five prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo